Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

被引：0

作者：

俞腾

机构：

[1] Med Coll

[2] Zhejiang Univ

[3] Dept Hematol

[4] 2nd Affil Hosp

来源：

China Medical Abstracts(Internal Medicine) | 2024年 / 41卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R733.1 [网状内皮系统肿瘤];

学科分类号：

摘要：

Objective To explore the efficacy and safety of fourthgeneration chimeric antigen receptor T-cells (CAR-T),which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19,in relapsed or refractory large B-cell lymphoma.Methods Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma.The efficacy and adverse effects were explored.

引用

页码：59 / 59

页数：1

共 50 条

[11] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 15 - 17
[12] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
Sano, Dahlia
Nastoupil, Loretta J.
Fowler, Nathan H.
Fayad, Luis
Hagemeister, F. B.
Lee, Hun Ju
Samaniego, Felipe
Wang, Michael
Rodriguez, Maria Alma
Iyer, Swaminathan P.
Parmar, Simrit
Steiner, Raphael
Nair, Ranjit
Adkins, Sherry
Arafat, Sara
Rao, Ahalya
Vallejo, Liliana
Hawkins, Misha
Chen, Yiming
Westin, Jason R.
Neelapu, Sattva S.
BLOOD, 2018, 132
[13] Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy
Jain, Michael D.
Ziccheddu, Bachisio
Coughlin, Caroline A.
Faramand, Rawan
Griswold, Anthony J.
Reid, Kayla M.
Landgren, Ola
Locke, Frederick L.
Maura, Francesco
Davila, Marco L.
Schatz, Jonathan H.
BLOOD, 2021, 138
[14] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPY
Jain, Michael
Ziccheddu, Bachisio
Coughlin, Caroline
Faramand, Rawan
Griswold, Anthony
Reid, Kayla
Landgren, Ola
Locke, Frederick
Maura, Francesco
Davila, Marco
Schatz, Jonathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703
[15] Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
Qu, Changju
Zou, Rui
Wang, Peng
Zhu, Qian
Kang, Liqing
Ping, Nana
Xia, Fan
Liu, Hailing
Kong, Danqing
Yu, Lei
Wu, Depei
Jin, Zhengming
FRONTIERS IN IMMUNOLOGY, 2022, 13
[16] Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma
Wang, Jiaxi
Jiang, Yirong
Luo, Min
Lu, Wenyi
He, Jixiang
Zhang, Meng
Yao, Zhuoxin
Jin, Xin
Xiao, Xia
Chen, Jianhang
Li, Guangchao
Ding, Wen
Zhou, Jie
Zhang, Zhiyin
Zhao, Mingfeng
CURRENT CANCER DRUG TARGETS, 2024,
[17] Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
Wang, Song-yun
An, Wan-hua
Wang, Ze-song
Wang, Wan-li
Zhang, Bin
Xu, Kai-lin
Guo, Shu-li
Gao, Ming
Li, Bo
Huang, Lei
Tian, Huan-huan
Guo, Wen-yi
Wang, Hui-rui
FRONTIERS IN IMMUNOLOGY, 2024, 15
[18] Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients
Qin, Yan
He, Xiaohui
Chen, Xinrui
Xie, Zucheng
Yang, Jianliang
Yang, Sheng
Liu, Peng
Zhou, Shengyu
Zhang, Changgong
Gui, Lin
Shi, Yuankai
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 356 - 364
[19] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang, Lefu
Li, Jingjing
Yang, Junfang
Zhang, Xian
Zhang, Min
He, Jiujiang
Zhang, Gailing
Li, Wenqian
Wang, Hui
Li, Jianqiang
Lu, Peihua
CELLS, 2022, 11 (24)
[20] Humanized CD19 CAR-T Cell Combined with Multiple Combination Treatments in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Wang, Jia
Yuan, Ji-jun
Mu, Juan
Li, Qing
Mou, Nan
Yang, Zhen-xing
Li, Wei
Li, Lanfang
Zhao, Peiqi
Wang, Xianhuo
Pu, Yedi
Zhang, Huilai
Deng, Qi
BLOOD, 2019, 134

← 1 2 3 4 5 →